Radioiodine scintigraphy with SPECT/CT: An important diagnostic tool for thyroid cancer staging and risk stratification

Journal of Nuclear Medicine

Volumn 53, Issue 5, 2012, Pages 754-764

  Avram, Anca M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Radioiodine fusion imaging; Thyroid cancer; Thyroid cancer staging and risk stratification

Indexed keywords

IODINE 131;

ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; CONSERVATIVE TREATMENT; DIAGNOSTIC IMAGING; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; PERSONALIZED MEDICINE; POSTOPERATIVE CARE; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID CANCER; THYROID SCINTISCANNING; TREATMENT PLANNING; TUMOR ABLATION;

ABLATION TECHNIQUES; HUMANS; IODINE RADIOISOTOPES; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RISK ASSESSMENT; THYROID NEOPLASMS;

EID: 84860754563     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.104133     Document Type: Article

References (78)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer. 1998;83:2638-2648. (Pubitemid 29019586)
3. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. January 4, 2012 [Epub ahead of print].
4. Volante M, Landolfi S, Chiusa L, et al. Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: A clinicopathologic study of 183 patients. Cancer. 2004;100:950-957. (Pubitemid 38222855)
5. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
6. Gemsenjäger E, Perren A, Seifert B, Schuler G, Schweizer I, Heitz PU. Lymph node surgery in papillary thyroid carcinoma. J Am Coll Surg. 2003;197:182-190. (Pubitemid 36927380)
7. Kupferman ME, Patterson M, Mandel SJ, LiVolsi V, Weber RS. Patterns of lateral neck metastasis in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2004;130:857-860. (Pubitemid 38915973)
8. Goropoulos A, Karamoshos K, Christodoulou A, et al. Value of the cervical compartments in the surgical treatment of papillary thyroid carcinoma. World J Surg. 2004;28:1275-1281. (Pubitemid 40941292)
9. Mercante G, Frasoldati A, Pedroni C, et al. Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: Results of a study in 445 patients. Thyroid. 2009;19:707-716.
10. Grebe SK, Hay ID. Thyroid cancer nodal metastases: Biologic significance and therapeutic considerations. Surg Oncol Clin N Am. 1996;5:43-63. (Pubitemid 26047382)
11. Scheumann GF, Gimm O, Wegener G, Hundeshagen H, Dralle H. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg. 1994;18:559-56.
12. Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid: Prognostic significance of lymph node metastasis and multifocality. Cancer. 2003;98:31-40. (Pubitemid 36741122)
13. Shah MD, Hall FT, Eski SJ, Witterick IJ, Walfish PG, Freeman JL. Clinical course of thyroid carcinoma after neck dissection. Laryngoscope. 2003;113: 2102-2107. (Pubitemid 38063829)
14. Wang TS, Dubner S, Sznyter LA, Heller KS. Incidence of metastatic well-differentiated thyroid cancer in cervical lymph nodes. Arch Otolaryngol Head Neck Surg. 2004;130:110-113. (Pubitemid 38095440)
15. Hay ID. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol. 2006; 94:692-700. (Pubitemid 44902068)
16. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26:879-885. (Pubitemid 36920280)
17. Jonklaas J, Cooper DS, Ain KB, et al. Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid. 2010;20:1423-1424.
18. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16:1229-1242. (Pubitemid 46080167)
19. Podnos YD, Smith DD, Wagman LD, Ellenhorn JD. Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope. J Surg Oncol. 2007;96:3-7. (Pubitemid 47015441)
20. Sacks W, Fung CH, Chang JT, Waxman A, Braunstein GD. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: A systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid. 2010;20:1235-1245.
21. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
22. Hughes DT, Haymart MR, Miller BS, Gauger PG, Doherty GM. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid. 2011;21:231-236.
23. Hay ID, Grant CS, van Heerden JA, Goellner JR, Ebersold JR, Bergstralh EJ. Papillary thyroid microcarcinoma: A study of 535 cases observed in a 50-year period. Surgery. 1992;112:1139-11467.
24. Hay ID, Hutchinson ME, Gonzalez-Losada T, et al. Papillary thyroid microcarcinoma: A study of 900 cases observed in a 60-year period. Surgery. 2008;144:980-987.
25. Strate SM, Lee EL, Childers JH. Occult papillary carcinoma of the thyroid with distant metastases. Cancer. 1984;54:1093-1100. (Pubitemid 14069831)
26. Ross DS, Litofsky D, Ain KB, et al. Recurrence after treatment of micropapillary thyroid cancer. Thyroid. 2009;19:1043-1048.
27. Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer. 2005;103:2269-2273. (Pubitemid 40686570)
28. Dietlein M, Verburg FA, Luster M, Reiners C, Pitoia F, Schicha H. One should not just read what one believes: The nearly irresolvable issue of producing truly objective, evidence-based guidelines for the management of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2011;38:793-798.
29. Bockisch A, Freudenberg LS, Schmidt D, Kuwert T. Hybrid imaging by SPECT/CT and PET/CT: Proven outcomes in cancer imaging. Semin Nucl Med. 2009;39:276-289.
30. Buck AK, Nekolla SG, Ziegler SI, Drzezga A. SPECT/CT. J Nucl Med. May 14, 2009 [Epub ahead of print].
31. Delbeke D, Schoder H, Martin WH, Wahl RL. Hybrid imaging (SPECT/CT and PET/CT): Improving therapeutic decisions. Semin Nucl Med. 2009;39: 308-340.
32. Even-Sapir E, Keidar Z, Bar-Shalom R. Hybrid imaging (SPECT/CT and PET/CT): Improving the diagnostic accuracy of functional/metabolic and anatomic imaging. Semin Nucl Med. 2009;39:264-275.
33. Mariani G, Bruselli L, Kuwert T, et al. A review on the clinical uses of SPECT/CT. Eur J Nucl Med Mol Imaging. 2010;37:1959-1985.
34. Gelfand MJ, Lemen LC. PET/CT and SPECT/CT dosimetry in children: The challenge to the pediatric imager. Semin Nucl Med. 2007;37:391-398. (Pubitemid 47247401)
35. Min JJ, Chung JK, Lee YJ, et al. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med. 2001;28:639-645. (Pubitemid 33815004)
36. Mian C, Barollo S, Pennelli G, et al. Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol (Oxf). 2008;68: 108-116. (Pubitemid 350243490)
37. Yamamoto Y, Nishiyama Y, Monden T, Matsumura Y, Satoh K, Ohkawa M. Clinical usefulness of fusion of 131I SPECT and CT images in patients with differentiated thyroid carcinoma. J Nucl Med. 2003;44:1905-1910. (Pubitemid 40022135)
38. Ruf J, Lehmkuhl L, Bertram H, et al. Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma. Nucl Med Commun. 2004;25:1177-1182. (Pubitemid 39614278)
39. Tharp K, Israel O, Hausmann J, et al. Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2004;31:1435-1442. (Pubitemid 39361941)
40. Aide N, Heutte N, Rame JP, et al. Clinical relevance of single-photon emission computed tomography/computed tomography of the neck and thorax in postablation 131I scintigraphy for thyroid cancer. J Clin Endocrinol Metab. 2009;94:2075-2084.
41. Chen L, Luo Q, Shen Y, et al. Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma. J Nucl Med. 2008;49:1952-1957.
42. Kohlfuerst S, Igerc I, Lobnig M, et al. Posttherapeutic 131I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen. Eur J Nucl Med Mol Imaging. 2009;36:886-893.
43. Schmidt D, Szikszai A, Linke R, Bautz W, Kuwert T. Impact of 131I SPECT/spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation. J Nucl Med. 2009;50:18-23.
44. Schmidt D, Linke R, Uder M, Kuwert T. Five months' follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by 131I-SPECT/CT at the first radioablation. Eur J Nucl Med Mol Imaging. 2010;37:699-705.
45. Wang H, Fu HL, Li JN, Zou RJ, Gu ZH, Wu JC. The role of single-photon emission computed tomography/computed tomography for precise localization of metastases in patients with differentiated thyroid cancer. Clin Imaging. 2009;33:49-54.
46. Mustafa M, Kuwert T, Weber K, et al. Regional lymph node involvement in T1 papillary thyroid carcinoma: A bicentric prospective SPECT/CT study. Eur J Nucl Med Mol Imaging. 2010;37:1462-1466.
47. Qiu ZL, Xu YH, Song HJ, Luo QY. Localization and identification of parapharyngeal metastases from differentiated thyroid carcinoma by 131I-SPECT/CT. Head Neck. 2011;33:171-177.
48. Grewal RK, Tuttle RM, Fox J, et al. The effect of post-therapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer. J Nucl Med. 2010;51:1361-1367.
49. Ciappuccini R, Heutte N, Trzepla G, et al. Postablation 131I scintigraphy with neck and thorax SPECT-CT and stimulated serum thyroglobulin level predict the outcome of patients with differentiated thyroid cancer. Eur J Endocrinol. 2011;164:961-969.
50. Wakabayashi H, Nakajima K, Fukuoka M, et al. Double-phase 131I whole body scan and 131I SPECT-CT images in patients with differentiated thyroid cancer: Their effectiveness for accurate identification. Ann Nucl Med. 2011;25:609-615.
51. Shapiro B, Rufini V, Jarwan A, et al. Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body 131-I scans in patients with thyroid cancer. Semin Nucl Med. 2000;30:115-132. (Pubitemid 30211275)
52. Mitchell G, Pratt BE, Vini L, McCready VR, Harmer CL. False positive 131I whole body scans in thyroid cancer. Br J Radiol. 2000;73:627-635. (Pubitemid 30392219)
53. Wong KK, Zarzhevsky N, Cahill JM, Frey KA, Avram AM. Hybrid SPECT-CT and PET-CT imaging of differentiated thyroid carcinoma. Br J Radiol. 2009;82:860-876.
54. Wong KK, Avram AM. Post-therapy I-131 thymic uptake demonstrated with SPECT/CT in a young girl with papillary thyroid carcinoma. Thyroid. 2008;18:919-920.
55. Dümcke CW, Madsen JL. Usefulness of SPECT/CT in the diagnosis of intrathoracic goiter versus metastases from cancer of the breast. Clin Nucl Med. 2007;32:156-159. (Pubitemid 46148406)
56. Macdonald W, Armstrong J. Benign struma ovarii in a patient with invasive papillary thyroid cancer: Detection with I-131 SPECT-CT. Clin Nucl Med. 2007;32:380-382. (Pubitemid 46659174)
57. Thust S, Fernando R, Barwick T, Mohan H, Clarke SE. SPECT/CT identification of post-radioactive iodine treatment false-positive uptake in a simple renal cyst. Thyroid. 2009;19:75-76.
58. Rachinsky I, Driedger A. Iodine-131 uptake in a menstruating uterus: Value of SPECT/CT in distinguishing benign and metastatic iodine-positive lesions. Thyroid. 2007;17:901-902. (Pubitemid 47606199)
59. Jong I, Taubman K, Schlicht S. Bronchiectasis simulating pulmonary metastases on iodine-131 scintigraphy in well-differentiated thyroid carcinoma. Clin Nucl Med. 2005;30:688-689. (Pubitemid 41361763)
60. Agriantonis DJ, Hall L, Wilson MA. Utility of SPECT/CT as an adjunct to planar whole body I-131 imaging: Liver metastasis from papillary thyroid cancer. Clin Nucl Med. 2009;34:247-248.
61. Aide N, Lehembre E, Gervais R, Bardet S. Unusual intratracheal metastasis of differentiated thyroid cancer accurately depicted by SPECT/CT acquisition after radioiodine ablation. Thyroid. 2007;17:1305-1306.
62. Qiu ZL, Luo QY. Erector spinae metastases from differentiated thyroid cancer identified by I-131 SPECT/CT. Clin Nucl Med. 2009;34:137-140.
63. von Falck C, Beer G, Gratz KF, Galanski M. Renal metastases from follicular thyroid cancer on SPECT/CT. Clin Nucl Med. 2007;32:751-752. (Pubitemid 47294881)
64. Zhao LX, Li L, Li FL, Zhao Z. Rectus abdominis muscle metastasis from papillary thyroid cancer identified by I-131 SPECT/CT. Clin Nucl Med. 2010;35:360-361.
65. Barwick T, Murray I, Megadmi H, et al. Single photon emission computed tomography (SPECT)/computed tomography using iodine-123 in patients with differentiated thyroid cancer: Additional value over whole body planar imaging and SPECT. Eur J Endocrinol. 2010;162:1131-1139.
66. Spanu A, Solinas ME, Chessa F, Sanna D, Nuvoli S, Madeddu G. 131I SPECT/CT in the follow-up of differentiated thyroid carcinoma: Incremental value versus planar imaging. J Nucl Med. 2009;50:184-190.
67. Wong KK, Zarzhevsky N, Cahill JM, Frey KA, Avram AM. Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma. AJR. 2008;191:1785-1794.
68. Wong KK, Sisson JC, Koral KF, Frey KA, Avram AM. Staging of differentiated thyroid carcinoma using diagnostic 131I SPECT/CT. AJR. 2010;195:730-736.
69. Avram AM, Doherty GM, Fig LM, Wong K. Diagnostic 131-I fusion SPECT-CT Imaging in postoperative thyroid cancer patients: What is the impact on staging? [abstract]. Thyroid. 2011;21(suppl 1):193.
70. Van Nostrand D. The benefits and risks of I-131 therapy in patients with welldifferentiated thyroid cancer. Thyroid. 2009;19:1381-1391.
71. Sisson JC, Dewaraja YK, Wizauer EJ, Giordano TJ, Avram AM. Thyroid carcinoma metastasis to skull with infringement of brain: Treatment with radioiodine. Thyroid. 2009;19:297-303.
72. Song H, He B, Prideaux A, et al. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med. 2006;47:1985-1994. (Pubitemid 47544986)
73. Prideaux AR, Song H, Hobbs RF, et al. Three-dimensional radiobiologic dosimetry: Application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med. 2007;48:1008-1016. (Pubitemid 46909931)
74. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892-2899. (Pubitemid 44271732)
75. Van Nostrand D, Aiken M, Atkins F, et al. The utility of radioiodine scans prior to iodine 131 ablation in patients with well-differentiated thyroid cancer. Thyroid. 2009;19:849-855.
76. Chen MK, Yasrebi M, Samii J, Staib LH, Doddamane I, Cheng DW. The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancer. Thyroid. 2012;22:304-309.
77. Van Nostrand D, Atkins F, Moreau S, et al. Utility of the radioiodine whole-body retention at 48 hours for modifying empiric activity of 131-iodine for the treatment of metastatic well-differentiated thyroid carcinoma. Thyroid. 2009;19: 1093-1098.
78. Sisson JC, Shulkin BL, Lawson S. Increasing efficacy and safety of treatments of patients with well-differentiated thyroid carcinoma by measuring body retentions of 131I. J Nucl Med. 2003;44:898-903. (Pubitemid 39663400)